Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04198922 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
A Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Moderate-Severe Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 6
- Study locations
NCT04198922 is a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Moderate-Severe Chronic Graft Versus Host Disease that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 51 participants, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT04198922, a Phase 2 study of Hematopoietic and Lymphoid Cell Neoplasm and Recurrent Moderate-Severe Chronic Graft Versus Host Disease, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Acalabrutinib
Study Locations (6)
Florida
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04198922
The ClinicalTrials.gov registry entry for NCT04198922 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (95% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT04198922 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04198922 about?
NCT04198922 is a clinical study titled "Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease". This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.
What is the current status of trial NCT04198922?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-12-11. Estimated completion is 2027-04-30.
What conditions does trial NCT04198922 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Moderate-Severe Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT04198922?
The interventions under investigation include: Questionnaire Administration (OTHER), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04198922?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04198922 being conducted?
This trial has 6 study locations across Florida, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
RECRUITING · Phase 2
-
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
ACTIVE NOT RECRUITING · Phase 2
-
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Hematopoietic and Lymphoid Cell Neoplasm
All registered trials for this condition
Recurrent Moderate-Severe Chronic Graft Versus Host Disease
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.